WAY stock forecast, quote, news & analysis
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations... Show more
Why Waystar Holding Corp. (WAY) Is Down -11% in the Last 30 Days
Key Takeaways
- WAY stock fell -11% over the past 30 days, driven by a sharp post-Q1 earnings selloff despite beating revenue and earnings estimates.
- Quarterly performance showed a -19% decline, marked by volatility with an intra-period peak followed by sector headwinds.
- Strong Q1 revenue growth of 22% year-over-year and AI-powered innovations offered tailwinds, but analyst price target reductions pressured sentiment.
- Healthcare payments software demand remains robust, supporting retention and bookings ahead of expectations.
- Macroeconomic factors like interest rates and healthcare spending trends influenced the broader downward trajectory.
Waystar Holding Corp. (WAY) Company Overview and Market Position
Waystar Holding Corp. (WAY) provides mission-critical cloud-based software that streamlines healthcare payments for providers, patients, and payers. Its platform simplifies complex revenue cycle management (RCM) processes, including claims processing, patient payments, and denial management. Operating in the competitive healthcare technology sector, Waystar differentiates through high retention rates, AI integrations, and scalability for large health systems. Recent fundamentals, such as expanding margins and platform adoption, underscore its exposure to growing RCM digitization, which has buoyed stock resilience amid volatility but faced valuation scrutiny in recent price movements.
Waystar Holding Corp. (WAY) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, WAY stock declined -11%, transitioning from around $24 to the latest price near $21.50. The period featured volatile swings, including a mid-April rally to $26.70 before retreating, culminating in a -15% single-day drop on elevated volume.
For the past quarter, shares dropped -19%, starting near $26.50 and experiencing range-bound trading with peaks above $26 and lows near $21. The movement was trend-driven downward overall, punctuated by short-term recoveries tied to product news, amid consistent selling pressure.
What Drove WAY Stock Price in the Last 30 Days
The primary catalyst for WAY's 30-day decline was the market's reaction to Q1 2026 earnings, released after market close. Despite revenue of $313.9 million surpassing estimates by 0.46% and adjusted EBITDA of $135.4 million (43% margin), shares gapped down sharply the next day. Investors appeared to focus on a perceived slight revenue shortfall in some views and trimmed analyst price targets, with firms like Goldman Sachs, JPMorgan, and UBS lowering theirs post-earnings.
Earlier in the period, positive momentum stemmed from AI-powered innovations showcased at the Spring event, including AltitudeAI tools and a recoupment solution, boosting shares temporarily. Elevated trading volume reflected shifting sentiment, while sector peers faced similar RCM pressures from payer dynamics.
What Drove WAY Stock Performance Over the Last Quarter
WAY's quarterly -19% slide reflected sustained sector challenges and valuation adjustments following its recent IPO. Early-period weakness tied to broader healthcare IT pullbacks amid high interest rates impacting capital spending by providers. A February low near $21 gave way to a recovery fueled by strong retention metrics and Iodine integration progress, peaking mid-April.
Macroeconomic conditions, including persistent inflation in healthcare costs and regulatory scrutiny on payments, weighed on sentiment. Institutional activity, such as fund sales, added downward pressure. However, core business strength—22% revenue growth and bookings beats—mitigated steeper losses, highlighting cumulative impacts from execution versus external headwinds.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms scanning thousands of tickers across various markets. These curated bots represent the most relevant and high-performing strategies, evaluated on metrics like win rate, average return, and consistency across short-term, swing, and long-term timeframes. Whether momentum-based, mean-reversion, or pattern recognition approaches, each bot details its performance history, risk profile, and applicable assets. This section helps investors discover automated tools tailored to current market trends without manual screening. Explore the Trending AI Robots for potential edges in stock analysis and trading.
WAY Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q2 earnings for updates on revenue cycle acceleration and AI adoption rates. Ongoing Iodine integration and new RCM tools could signal platform expansion. Industry trends in healthcare digitization, payer-provider negotiations, and denial rates remain key. Macro factors like Federal Reserve rate decisions and healthcare spending forecasts may influence demand. Potential risks include competitive pressures in cloud RCM and regulatory changes in payments processing, alongside catalysts from partnerships or large-client wins.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
WAY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for WAY turned positive on June 24, 2026. Looking at past instances where WAY's MACD turned positive, the stock continued to rise in of 18 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 25, 2026. You may want to consider a long position or call options on WAY as a result. In of 36 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
WAY moved above its 50-day moving average on June 30, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where WAY advanced for three days, in of 120 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
WAY broke above its upper Bollinger Band on June 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for WAY entered a downward trend on June 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.843) is normal, around the industry mean (7.366). P/E Ratio (25.836) is within average values for comparable stocks, (50.081). WAY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.153). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (2.819) is also within normal values, averaging (5.651).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. WAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry